Introduction

Poly Medicure Limited (NSE: POLYMED) has informed stock exchanges that it has received an order from the Office of the Divisional Commissioner, Government of NCT of Delhi, relating to alleged deficit stamp duty on certain historical share allotments. The order directs the company to pay over ₹2.5 crore, including stamp duty and penalties. However, Poly Medicure has stated that it disagrees with the findings, believes the order suffers from significant jurisdictional and procedural infirmities, and is pursuing legal remedies to challenge the decision. The development has attracted investor attention due to its regulatory and financial implications.

Key Highlights

• Poly Medicure has received a stamp duty order from Delhi Revenue authorities.
• The order relates to certain historical share allotments undertaken by the company.
• Authorities have alleged a deficit stamp duty liability of ₹1.00 crore.
• A penalty of ₹1.50 crore has also been imposed.
• Total financial exposure under the order exceeds ₹2.50 crore.
• The company believes the order contains jurisdictional and procedural infirmities.
• Poly Medicure is pursuing legal remedies to challenge the order.
• Management does not expect any material impact on business operations or financial performance.

Why This News Matters

Regulatory and tax-related disputes are closely tracked by investors because they can create potential financial liabilities and legal uncertainties. In Poly Medicure’s case, the dispute centers on the interpretation of stamp duty provisions applicable to share allotments. While the authorities have raised a substantial demand, the company has maintained that it had already discharged the applicable stamp duty obligations and believes the proceedings are not legally sustainable. The outcome of the legal challenge could therefore be an important factor for investors monitoring regulatory developments surrounding the company.

Detailed Analysis

According to the exchange filing, proceedings were initiated by the Office of the Divisional Commissioner, Government of NCT of Delhi, through the Collector of Stamps regarding stamp duty payable on certain share allotments made by Poly Medicure. The company had received show-cause notices in February and March 2026 relating to allotments undertaken in November 2021 and August 2022.

Following the proceedings, the authority issued an order dated June 15, 2026, holding the company liable to pay alleged deficit stamp duty of ₹1,00,25,820 along with a penalty of ₹1,50,00,000. The company noted that while the original notices related to specific share allotments, the final order also included additional allotments that were not part of the show-cause proceedings.

Poly Medicure has argued that it had duly paid the applicable stamp duty through depositories such as NSDL and CDSL and that the proceedings initiated under Article 19 of Schedule IA of the Indian Stamp Act were not maintainable in view of Sections 9A(2) and 9A(3) of the Act. The company has obtained legal advice and believes there are strong grounds to challenge the order before the appropriate forum.

Importantly, management stated that it does not expect any material impact on the company’s financial position, operations, or business activities arising from the order.

Potential Investor Impact

The development represents a regulatory and legal matter rather than an operational challenge. Although the demand amount exceeds ₹2.5 crore, Poly Medicure has clearly stated its intention to challenge the order and has indicated that it expects no material impact on its business. As a result, investor focus is likely to remain on legal proceedings, appellate developments, and management’s future disclosures regarding the matter.

What Investors Should Watch

Investors should monitor the company’s legal challenge, any stay orders or appellate proceedings, updates from regulatory authorities, and management commentary regarding the dispute. Further disclosures on the progress of the case may provide greater clarity on the potential financial and legal implications.

Bottom Line

Poly Medicure has received a regulatory order imposing alleged deficit stamp duty and penalties totaling more than ₹2.5 crore in relation to certain historical share allotments. However, the company disputes the findings, believes it has strong legal grounds to challenge the decision, and expects no material impact on its operations or financial performance. Going forward, investors are likely to closely track the progress of legal proceedings and any further developments related to the matter.

FAQs

Q1. What is the latest news about Poly Medicure?

Poly Medicure has received a stamp duty and penalty order from Delhi authorities and plans to challenge it through legal remedies.

Q2. What is the total demand raised against Poly Medicure?

The order includes alleged deficit stamp duty of ₹1.00 crore and a penalty of ₹1.50 crore, taking the total demand above ₹2.5 crore.

Q3. Why was the order issued?

The matter relates to stamp duty obligations associated with certain historical share allotments undertaken by the company.

Q4. Does Poly Medicure agree with the order?

No. The company has stated that it believes the order suffers from jurisdictional and procedural infirmities and intends to challenge it legally.

Q5. What should investors monitor going forward?

Investors should track legal proceedings, appellate developments, and future company disclosures regarding the dispute.